User menu

Results from early programmatic implementation of Xpert MTB/RIF testing in nine countries.

Bibliographic reference Creswell, Jacob ; Codlin, Andrew J ; André, Emmanuel ; Micek, Mark A ; Bedru, Ahmed ; et. al. Results from early programmatic implementation of Xpert MTB/RIF testing in nine countries.. In: BMC Infectious Diseases, Vol. 14, no.2 (02/01/2014)
Permanent URL http://hdl.handle.net/2078.1/138045
  1. World Health Organization: Global Tuberculosis Report 2013. 2012, Geneva, Switzerland: World Health Organization
  2. World Health Organization: Policy Statement: Automated real-time Nucleic Acid Amplification Technology for Rapid and Simultaneous Detection of Tuberculosis and Rifampicin Resistance: Xpert MTB/RIF System. 2011, Geneva, Switzerland: World Health Organization
  3. World Health Organization: Rapid Implementation of the Xpert MTB/RIF diagnostic test. 2011, Geneva, Switzerland: World Health Organization
  4. Boehme Catharina C., Nabeta Pamela, Hillemann Doris, Nicol Mark P., Shenai Shubhada, Krapp Fiorella, Allen Jenny, Tahirli Rasim, Blakemore Robert, Rustomjee Roxana, Milovic Ana, Jones Martin, O'Brien Sean M., Persing David H., Ruesch-Gerdes Sabine, Gotuzzo Eduardo, Rodrigues Camilla, Alland David, Perkins Mark D., Rapid Molecular Detection of Tuberculosis and Rifampin Resistance, 10.1056/nejmoa0907847
  5. Steingart KR, Sohn H, Schiller I, Kloda LA, Boehme CC, Pai M, Dendukuri N: Xpert® MTB/RIF assay for pulmonary tuberculosis and rifampicin resistance in adults. Cochrane Database Syst Rev. 2013, 1: CD009593-
  6. WHO monitoring of MTB/RIF roll-out. [ http://www.who.int/tb/laboratory/mtbrifrollout/en/index.html ]
  7. Bates Matthew, O'Grady Justin, Maeurer Markus, Tembo John, Chilukutu Lophina, Chabala Chishala, Kasonde Richard, Mulota Peter, Mzyece Judith, Chomba Mumba, Mukonda Lukundo, Mumba Maxwell, Kapata Nathan, Rachow Andrea, Clowes Petra, Hoelscher Michael, Mwaba Peter, Zumla Alimuddin, Assessment of the Xpert MTB/RIF assay for diagnosis of tuberculosis with gastric lavage aspirates in children in sub-Saharan Africa: a prospective descriptive study, 10.1016/s1473-3099(12)70245-1
  8. Lawn SD, Kerkhoff AD, Vogt M, Wood R: High diagnostic yield of tuberculosis from screening urine samples from HIV-infected patients with advanced immunodeficiency using the Xpert MTB/RIF assay. J Acquir Immune Defic Syndr. 2012, 60 (3): 289-294.
  9. Walters E, Gie RP, Hesseling AC, Friedrich SO, Diacon AH, Gie RP: Rapid diagnosis of pediatric intrathoracictuberculosis from stool samples using the Xpert MTB/RIF assay: a pilot study. Pediatr Infect Dis J. 2012, 31 (12): 1316-
  10. Friedrich SO, von Groote-Bidlingmaier F, Diacon AH: Xpert MTB/RIF assay for the diagnosis of pleural tuberculosis. J Clin Microbiol. 2011, 49 (12): 4341-4342.
  11. Zar H. J., Workman L., Isaacs W., Munro J., Black F., Eley B., Allen V., Boehme C. C., Zemanay W., Nicol M. P., Rapid Molecular Diagnosis of Pulmonary Tuberculosis in Children Using Nasopharyngeal Specimens, 10.1093/cid/cis598
  12. Barnard M., Gey van Pittius N. C., van Helden P. D., Bosman M., Coetzee G., Warren R. M., The Diagnostic Performance of the GenoType MTBDRplus Version 2 Line Probe Assay Is Equivalent to That of the Xpert MTB/RIF Assay, 10.1128/jcm.01958-12
  13. Williamson Deborah A., Basu Indira, Bower James, Freeman Joshua T., Henderson Gillian, Roberts Sally A., An evaluation of the Xpert MTB/RIF assay and detection of false-positive rifampicin resistance in Mycobacterium tuberculosis, 10.1016/j.diagmicrobio.2012.06.013
  14. Dheda K, Ruhwald M, Theron G, Peter J, Yam WC: Point-of-care diagnosis of tuberculosis: past, present and future. Respirology. 2012, 18 (2): 217-232.
  15. Peters D, Grant T, Jonny P, Keertan D: Should Xpert® MTB/RIF be rolled out in low-income countries? [correspondence]. Int J Tuberc Lung Dis. 2012, 16 (5): 702-703.
  16. Trébucq A, Harries AD, Rieder HL: In reply to ‘Should Xpert® MTB/RIF be rolled out in low-income countries?’. Int J Tuberc Lung Dis. 2012, 16 (5): 703-704.
  17. Singh Jerome Amir, Bhan Anant, The ethics of national tuberculosis programmes in low-income countries not rolling out Xpert ® MTB/RIF, 10.5588/ijtld.11.0728
  18. Dowdy David W., Cattamanchi Adithya, Steingart Karen R., Pai Madhukar, Is Scale-Up Worth It? Challenges in Economic Analysis of Diagnostic Tests for Tuberculosis, 10.1371/journal.pmed.1001063
  19. Vassall A, van Kampen S, Sohn H, Michael JS, John KR, den Boon S, Davis JL, Whitelaw A, Nicol MP, Gler MT, Khaliqov A, Zamudio C, Perkins MD, Boehme CC, Cobelens F: Rapid diagnosis of tuberculosis with the Xpert MTB/RIF assay in high burden countries: a cost-effectiveness analysis. PLoS Med. 2011, 8 (11): e1001120-
  20. Evans CA: GeneXpert—a game-changer for tuberculosis control?. PLoS Med. 2011, 8 (7): e1001064-
  21. Small Peter M., Pai Madhukar, Tuberculosis Diagnosis — Time for a Game Change, 10.1056/nejme1008496
  22. Denkinger CM, Grenier J, Minion J, Pai M: Promise versus reality: optimism bias in package inserts for tuberculosis diagnostics. J Clin Microbiol. 2012, 50 (7): 2455-2461.
  23. TB REACH Website. [ http://www.stoptb.org/global/awards/tbreach/about.asp .]
  24. Public-private partnership announces immediate 40 percent cost reduction for rapid TB test. [ http://www.usaid.gov/news-information/press-releases/public-private-partnership-announces-immediate-40-percent-cost .]
  25. Cepheid announces update on Xpert® test availability. [ http://ir.cepheid.com/releasedetail.cfm?releaseid=732096 .]
  26. Trébucq A., Enarson D.A., Chiang C.Y., Van Deun A., Harries A.D., Boillot F., Detjen A., Fujiwara P.I., Graham S.M., Monedero I., Rusen I.D., Rieder H.L., Xpert® MTB/RIF for national tuberculosis programmes in low-income countries: when, where and how?, 10.5588/ijtld.11.0392
  27. Lawn SD, Mwaba P, Bates M, Piatek A, Alexander H, Marais BJ, Cuevas LE, McHugh TD, Zijenah L, Kapata N, Abubakar I, McNerney R, Hoelscher M, Memish ZA, Migliori GB, Kim P, Maeurer M, Schito M, Zumla A: Advances in tuberculosis diagnostics: the Xpert MTB/RIF assay and future prospects for a point-of-care test. Lancet Infect Dis. 2013, 13: 349-361.
  28. Stevens W: “South Africa’s “Reality Check” >1 million Xpert tests.” Global laboratory initiative. “Xpert SMS – introducing automated MTB/RIF reporting into running projects. 5th Annual GLI Meeting Advances in TB Diagnostic Services. 2013, Annecy, France: Transforming TB Care & Control, http://www.stoptb.org/wg/gli/assets/html/GLI5/GLI%205th%20meeting%20SA%20perspective%20v7.pdf ,
  29. World Health Organization: Systematic screening for active tuberculosis – principles and recommendations. 2013, Geneva, Switzerland: World Health Organization
  30. Codlin AJ, Javaid M, Qazi F, Khan MS: Novel methodology to assess sputum smear microscopy quality in private laboratories. BMC Infect Dis. 2012, 12: 331-
  31. World Health Organization: Policy Guidance on Xpert MTB/RIF testing. 2013, Geneva, Switzerland: World Health Organization, http://www.stoptb.org/wg/gli/assets/documents/WHO%20Policy%20Statement%20on%20Xpert%20MTB-RIF%202013%20pre%20publication%2022102013.pdf ,
  32. GeneXpertDx System: Operator Manual Software version 4.0. e-dok.rm.dk/e-dok/e_702615.nsf/$CXIV/ATTACH-RMAP-8QVAXS/$FILE/Operator%20Manual%20Rev%20C[1].1%204.0%20Version%20GX%20Dx%20Operator%20Manual_EN%20Mar11.pdf
  33. Khan A: “XpertSMS – introducing automated MTB/RIF reporting into running rojects.” Global laboratory initiative. “Xpert SMS – introducing automated MTB/RIF reporting into running projects. 5th Annual GLI Meeting Advances in TB Diagnostic Services. 2013, Annecy, France: Transforming TB Care & Control, http://www.stoptb.org/wg/gli/assets/html/GLI5/GLI_2013_XpertSMS_IRD_v5.pdf ,
  34. Varaine F, Ardizzoni E: “Xpert MTB/RIF ® implementation in MSF projects: First results.” Global Laboratory Initiative. 4th Annual GLI Meeting/Consultation of the WHO/GLI SRL Network/Early Implementers Meeting on Xpert MTB/RIF roll-out, Annecy, France, April 17–19. 2012, http://www.stoptb.org/wg/gli/assets/html/day%202/Varaine%20-%20MSF%20projects.pdf ,
  35. World Health Organization: Multidrug and extensively drug-resistant TB (M/XDR-TB): 2010 Global Report on Surveillance and response. 2010, Geneva, Switzerland: World Health Organization
  36. Pai NP, Vadnais C, Denkinger C, Engel N, Pai M: Point-of-care testing for infectious diseases: diversity, complexity, and barriers in low- and middle-income countries. PLoS Med. 2012, 9 (9): e1001306-
  37. Theron G, Zijenah L, Chanda D, Clowes P, Rachow A, Lesosky M, Bara W, Mungofa S, Pai M, Hoelscher M, Dowdy D, Pym A, Mwaba P, Mason P, Peter J, Dheda K, for the TB-NEAT team: Feasibility, accuracy, and clinical effect of point-of-care Xpert MTB/RIF testing for tuberculosis in primary-care settings in Africa: a multicentre, randomised, controlled trial. Lancet. 2013, doi:10.1016/S0140-6736(13)62073-5. [Epub ahead of print]
  38. Denkinger Claudia M., Nicolau Ioana, Ramsay Andrew, Chedore Pamela, Pai Madhukar, Are peripheral microscopy centres ready for next generation molecular tuberculosis diagnostics?, 10.1183/09031936.00081113
  39. Global laboratory initiative. 4th annual GLI meeting/consultation of the WHO/GLI SRL network/early implementers meeting on Xpert MTB/RIF roll-out, Annecy, France, April 17–19, 2012. [ http://www.stoptb.org/wg/gli/assets/html/4th%20GLI%20meeting%2017-19%20April%202012%20AGENDA.htm .]
  40. World Health Organization: Definitions and Reporting Framework for Tuberculosis – 2013 revision. 2013, Geneva, Switzerland: World Health Organization